Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.

Crohn’s disease, disease burden may weaken vedolizumab efficacy in IBD patients

29 Oct 2018

Vedolizumab is safe and effective in the treatment of inflammatory bowel disease (IBD) patients, according to a study. However, Crohn’s disease (CD) and a more severe disease appear to impair both short- and long-term effectiveness of the drug.

Researchers looked at 508 patients (median age 42 years; 54.8 percent female; 50.9 percent had CD) who received 1 induction dose of vedolizumab, with a median follow-up of 10 months. Effectiveness was measured using the Harvey-Bradshaw index (HBI) in CD and the Partial Mayo Score (PMS) in ulcerative colitis (UC).  Responses to treatment in the short term (week 14) and the long-term were evaluated.

Overall, 46.8 percent of patients achieved remission while 15.7 percent had clinical response at week 14. CD, previous surgery, higher C-reactive protein (CRP) concentration and greater disease severity at baseline emerged as significant predictors of impaired response.

Vedolizumab discontinuation rate was 37 percent per patient-year of follow-up (27.6 percent in UC; 45.3 percent in CD; p<0.01). Factors significantly associated with lower treatment durability included CD, anaemia at baseline, steroids during induction and CRP concentration.

Adverse events occurred in 7.1 percent of patients overall. The most commonly reported were infections such as those of the sinopulmonary and gastrointestinal tracts.

Additional clinical trials are needed to place vedolizumab in the therapeutic algorithm of IBD patients, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.